These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 19717467)

  • 1. Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation.
    Ho VT; Vanneman M; Kim H; Sasada T; Kang YJ; Pasek M; Cutler C; Koreth J; Alyea E; Sarantopoulos S; Antin JH; Ritz J; Canning C; Kutok J; Mihm MC; Dranoff G; Soiffer R
    Proc Natl Acad Sci U S A; 2009 Sep; 106(37):15825-30. PubMed ID: 19717467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myeloablative allogeneic bone marrow transplant using T cell depleted allografts followed by post-transplant GM-CSF in high-risk myelodysplastic syndromes.
    Warlick ED; O'Donnell PV; Borowitz M; Grupka N; Decloe L; Garrett-Mayer E; Borrello I; Brodsky R; Fuchs E; Huff CA; Luznik L; Matsui W; Ambinder R; Jones RJ; Smith BD
    Leuk Res; 2008 Sep; 32(9):1439-47. PubMed ID: 18261793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized, double-blinded, phase 2 trial.
    Ho VT; Kim HT; Brock J; Galinsky I; Daley H; Reynolds C; Weber A; Pozdnyakova O; Severgnini M; Nikiforow S; Cutler C; Koreth J; Alyea EP; Antin JH; Gooptu M; Romee R; Shapiro R; Chen YB; Rosenblatt J; Avigan D; Hodi FS; Dranoff G; Wu CJ; Ritz J; Soiffer RJ
    Blood Adv; 2022 Apr; 6(7):2183-2194. PubMed ID: 34807983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells.
    Burkhardt UE; Hainz U; Stevenson K; Goldstein NR; Pasek M; Naito M; Wu D; Ho VT; Alonso A; Hammond NN; Wong J; Sievers QL; Brusic A; McDonough SM; Zeng W; Perrin A; Brown JR; Canning CM; Koreth J; Cutler C; Armand P; Neuberg D; Lee JS; Antin JH; Mulligan RC; Sasada T; Ritz J; Soiffer RJ; Dranoff G; Alyea EP; Wu CJ
    J Clin Invest; 2013 Sep; 123(9):3756-65. PubMed ID: 23912587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of relapsing leukemia after allogeneic blood stem cell transplantation by using dose-reduced conditioning followed by donor blood stem cells and GM-CSF.
    Platzbecker U; Thiede C; Freiberg-Richter J; Helwig A; Mohr B; Prange G; Füssel M; Köhler T; Ehninger G; Bornhäuser M
    Ann Hematol; 2001 Mar; 80(3):144-9. PubMed ID: 11320898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma.
    Soiffer R; Hodi FS; Haluska F; Jung K; Gillessen S; Singer S; Tanabe K; Duda R; Mentzer S; Jaklitsch M; Bueno R; Clift S; Hardy S; Neuberg D; Mulligan R; Webb I; Mihm M; Dranoff G
    J Clin Oncol; 2003 Sep; 21(17):3343-50. PubMed ID: 12947071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.
    Lee DA; Denman CJ; Rondon G; Woodworth G; Chen J; Fisher T; Kaur I; Fernandez-Vina M; Cao K; Ciurea S; Shpall EJ; Champlin RE
    Biol Blood Marrow Transplant; 2016 Jul; 22(7):1290-1298. PubMed ID: 27090958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Activating NKG2C Receptor Is Significantly Reduced in NK Cells after Allogeneic Stem Cell Transplantation in Patients with Severe Graft-versus-Host Disease.
    Kordelas L; Steckel NK; Horn PA; Beelen DW; Rebmann V
    Int J Mol Sci; 2016 Oct; 17(11):. PubMed ID: 27801784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
    Chen YB; Coughlin E; Kennedy KF; Alyea EP; Armand P; Attar EC; Ballen KK; Cutler C; Dey BR; Koreth J; McAfee SL; Spitzer TR; Antin JH; Soiffer RJ; Ho VT
    Biol Blood Marrow Transplant; 2013 Jun; 19(6):981-7. PubMed ID: 23562738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Study of Human Leukocyte Antigen Mismatched Cellular Therapy (Stem Cell Microtransplantation) in High-Risk Myelodysplastic Syndrome or Transformed Acute Myelogenous Leukemia.
    Hu KX; Sun QY; Guo M; Qiao JX; Yu CL; Qiao JH; Dong Z; Sun WJ; Zuo HL; Huang YJ; Cai B; Ai HS
    Stem Cells Transl Med; 2016 Apr; 5(4):524-9. PubMed ID: 26838271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful therapy of metastatic cancer using tumor vaccines in mixed allogeneic bone marrow chimeras.
    Luznik L; Slansky JE; Jalla S; Borrello I; Levitsky HI; Pardoll DM; Fuchs EJ
    Blood; 2003 Feb; 101(4):1645-52. PubMed ID: 12406877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical course and predictive factors for cyclosporin-induced autologous graft-versus-host disease after autologous haematopoietic stem cell transplantation.
    Baron F; Gothot A; Salmon JP; Hermanne JP; Pierard GE; Fillet G; Beguin Y
    Br J Haematol; 2000 Dec; 111(3):745-53. PubMed ID: 11122133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrospective Evaluation of Relationship Between Iron Overload and Transplantation Complications in Pediatric Patient Who Underwent Allogeneic Stem Cell Transplantation Due to Acute Leukemia and Myelodysplastic Syndrome.
    Küpesiz FT; Hazar V; Eker N; Guler E; Yesilipek MA; Tuysuz G; Kupesiz A
    J Pediatr Hematol Oncol; 2020 Jul; 42(5):e315-e320. PubMed ID: 32427707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiogenic cytokines are antibody targets during graft-versus-leukemia reactions.
    Piesche M; Ho VT; Kim H; Nakazaki Y; Nehil M; Yaghi NK; Kolodin D; Weiser J; Altevogt P; Kiefel H; Alyea EP; Antin JH; Cutler C; Koreth J; Canning C; Ritz J; Soiffer RJ; Dranoff G
    Clin Cancer Res; 2015 Mar; 21(5):1010-8. PubMed ID: 25538258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML).
    Borrello IM; Levitsky HI; Stock W; Sher D; Qin L; DeAngelo DJ; Alyea EP; Stone RM; Damon LE; Linker CA; Maslyar DJ; Hege KM
    Blood; 2009 Aug; 114(9):1736-45. PubMed ID: 19556425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon-α: A Potentially Effective Treatment for Minimal Residual Disease in Acute Leukemia/Myelodysplastic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation.
    Mo XD; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1939-47. PubMed ID: 26116088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Granulocyte-macrophage colony-stimulating factor increases the proportion of circulating dendritic cells after autologous but not after allogeneic hematopoietic stem cell transplantation.
    Eksioglu EA; Kielbasa J; Eisen S; Reddy V
    Cytotherapy; 2011 Aug; 13(7):888-96. PubMed ID: 21609205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term outcomes of granulocyte colony-stimulating factor-combined conditioning in allogeneic hematopoietic stem cell transplantation from HLA-identical family donors for myeloid malignancies.
    Konuma T; Kato S; Ishii H; Oiwa-Monna M; Asano S; Tojo A; Takahashi S
    Leuk Res; 2015 Jun; 39(6):625-31. PubMed ID: 25888304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes.
    Lee HC; Saliba RM; Rondon G; Chen J; Charafeddine Y; Medeiros LJ; Alatrash G; Andersson BS; Popat U; Kebriaei P; Ciurea S; Oran B; Shpall E; Champlin R
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1948-54. PubMed ID: 26183077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.